Search

Your search keyword '"Van Elssen, Catharina"' showing total 6 results
Start Over Author "Van Elssen, Catharina" Publisher american society of hematology
6 results on '"Van Elssen, Catharina"'

1. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

2. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

3. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, primary, Pabst, Thomas, additional, Maertens, Johan, additional, Gradowska, Patrycja, additional, Biemond, Bart J., additional, Spertini, Olivier, additional, Vellenga, Edo, additional, Griskevicius, Laimonas, additional, Tick, Lidwine W., additional, Jongen-Lavrencic, Mojca, additional, van Marwijk Kooy, Marinus, additional, Vekemans, Marie-Christiane, additional, van der Velden, Walter J. F. M., additional, Beverloo, Berna, additional, Michaux, Lucienne, additional, Graux, Carlos, additional, Deeren, Dries, additional, de Weerdt, Okke, additional, van Esser, Joost W. J., additional, Bargetzi, Mario, additional, Klein, Saskia K., additional, Gadisseur, Alain, additional, Westerweel, Peter E., additional, Veelken, Hendrik, additional, Gregor, Michael, additional, Silzle, Tobias, additional, van Lammeren-Venema, Daniëlle, additional, Moors, Ine, additional, Breems, Dimitri A., additional, Hoogendoorn, Mels, additional, Legdeur, Marie-Cecile J. C., additional, Fischer, Thomas, additional, Kuball, Juergen, additional, Cornelissen, Jan, additional, Porkka, Kimmo, additional, Juliusson, Gunnar, additional, Meyer, Peter, additional, Höglund, Martin, additional, Gjertsen, Bjorn T., additional, Janssen, Jeroen J. W. M., additional, Huls, Gerwin, additional, Passweg, Jakob, additional, Cloos, Jacqueline, additional, Valk, Peter J. M., additional, van Elssen, Catharina H. M. J., additional, Manz, Markus G., additional, Floisand, Yngvar, additional, and Ossenkoppele, Gert J., additional

Published
2021
Full Text
View/download PDF

5. In vitro–differentiated T/natural killer–cell progenitors derived from human CD34+ cells mature in the thymus

Author

Meek, Bob, primary, Cloosen, Silvie, additional, Borsotti, Chiara, additional, Van Elssen, Catharina H. M. J., additional, Vanderlocht, Joris, additional, Schnijderberg, Melanie C. A., additional, van der Poel, Marjolein W. M., additional, Leewis, Bas, additional, Hesselink, Reinout, additional, Manz, Markus G., additional, Katsura, Yoshimoto, additional, Kawamoto, Hiroshi, additional, Germeraad, Wilfred T. V., additional, and Bos, Gerard M. J., additional

Published
2010
Full Text
View/download PDF

6. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Subjects
hemic and lymphatic diseases, 610 Medizin und Gesundheit, 3. Good health
Abstract

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

Catalog

Books, media, physical & digital resources
See catalog results